Pharmaceutical intelligence for JCR Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 8, 2026

Phase I/II Trial of JR-446 for MPS IIIB Initiated by JCR Pharmaceuticals

A Phase I/II trial of JR-446 is underway to evaluate its safety and early clinical effects in young patients with MPS IIIB.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 8, 2026

Phase I/II Trial of JR-446 for MPS IIIB Initiated by JCR Pharmaceuticals

A Phase I/II trial of JR-446 is underway to evaluate its safety and early clinical effects in young patients with MPS IIIB.

Competitive activity

No signals indexed for this entity yet.

Assets

Phase →

Therapeutic areas

Genetic Disorders →

Mucopolysaccharidosis →

Indications

Genetic Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.